Imagine a tiny, harmless sonar for your bones that can see holes as small as microscopic pores. Instead of just measuring how dense a bone is, this tool looks at the actual quality and structure. It's like checking if a bridge is strong by looking at the rust inside the beams rather than just weighing the steel.
Current gold standard BMD scans fail to detect 80% of people at risk of fragility fractures. This leads to high hospital costs and missed opportunities for early prevention.
A mobile quantitative ultrasound device and software for non-invasive bone biomarker measurement. It includes a user-friendly interface and a hardware-independent module architecture.
If you are a clinic owner dealing with the inability to screen for osteoporosis on-site — this project developed a mobile ultrasound system that allows for early diagnosis in primary care facilities. This removes the need for patients to travel to specialized hospitals for BMD scans.
If you are a hardware manufacturer dealing with the limitations of current BMD gold standards — this project developed a patented quantitative ultrasound device that measures cortical bone quality. It provides a multifactorial analysis of fracture risk that overcomes the weaknesses of BMD.
If you are an insurer dealing with huge healthcare costs from osteoporosis hospitalizations — this project developed a screening technology for prevention. By detecting the 80% of at-risk people that BMD misses, it can reduce expensive fragility fracture treatments.
Based on available project data, the specific unit price or cost of the device is not mentioned.
The project is moving toward market entry by developing the product to TRL9 and creating a software module architecture that allows for hardware independence.
The technology utilizes patented intelligent algorithms for measuring cortical bone quality at the microscopic pore level.
The device complies with EN 60601 for medical ultrasound devices and had an MDR audit scheduled for July 2024 for CE certification.
The project period runs from 2023-02-01 to 2026-05-31, with the first year focused on hardware, software, and clinical evaluation preparation.
The project is led by a single German SME, POROUS GMBH, with a 100% industry ratio. This lean structure suggests a fast-track approach to commercialization, focusing entirely on product development and market entry without the overhead of academic partners.
Contact POROUS GMBH in Germany for licensing or partnership inquiries.
Contact us to explore integration of quantitative ultrasound into your diagnostic portfolio.
